Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXZGKI)

Drug Name

G009 Drug Info

Synonyms

Beta-(1-3)-Glucan with beta-(1-6) side chain isolated from the Basidiomycetes Ganoderma lucidum

Indication

Disease Entry	ICD 11	Status	REF
Immune System disease	4A01-4B41	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Lipid peroxidation (LPO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
T-817MA	DMD72F4	Alzheimer disease	8A20	Phase 2	[2]
RAXOFELAST	DMK2E0N	Ischemia	8B10-8B11	Phase 2	[3]
TAK-218	DM7S69Q	Neurological disorder	6B60	Discontinued in Phase 2	[4]
U-104067F	DMC94D2	Neurological disorder	6B60	Discontinued in Phase 1	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Inhibition of lipid peroxidation and oxidative DNA damage by Ganoderma lucidum. Phytother Res. 2001 May;15(3):245-9.
2	A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. Neuropharmacology. 2008 Oct;55(5):654-60.
3	Lipid peroxidation inhibition by raxofelast improves angiogenesis and wound healing in experimental burn wounds. Shock. 2005 Jul;24(1):85-91.
4	ESR study on the antioxidant activity of TAK-218 in biological model membranes. Chem Pharm Bull (Tokyo). 2000 Jun;48(6):784-92.
5	Two novel pyrrolopyrimidine lipid peroxidation inhibitors U-101033E and U-104067F protect facial motor neurons following neonatal axotomy. Exp Neurol. 1996 Oct;141(2):304-9.